Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL9235516 | 1.00 | LMNA (0.71) | LMNAMEN1KMT2ACA1CA2 | |
| Tromethamine SCHEMBL8668436 | 1.00 | LMNA (0.71) | LMNAMEN1KMT2ACA1CA2 | |
| Tromethamine SCHEMBL14876950 | 0.90 | MEN1 (0.67) | LMNAMEN1KMT2AOR51E2ARG1 | |
| Tromethamine SCHEMBL194002 | 0.87 | LMNA (0.62) | LMNAMEN1KMT2AARG1ARG2 | |
| Tromethamine SCHEMBL4581519 | 0.87 | LMNA (0.62) | LMNAMEN1KMT2AARG1ARG2 | |
| Tromethamine SCHEMBL7347818 | 0.87 | LMNA (0.62) | LMNAMEN1KMT2AARG1ARG2 | |
| Tromethamine SCHEMBL6905131 | 0.86 | LMNA (0.71) | LMNAMEN1KMT2AOR51E2KDM4E | |
| Tromethamine SCHEMBL3696191 | 0.84 | — | — | |
| Tromethamine SCHEMBL975 | 0.84 | — | — | |
| Tromethamine SCHEMBL17484 | 0.84 | MEN1 (1.00) | LMNAMEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| CN-112300435-A | Environment-friendly polyurethane foaming agent and preparation method thereof | 宋庆红 | 2021-02-02 | — | — | CN | claimed |
| EP-2278997-B1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORP (US) | 2016-08-10 | — | — | EP | claimed |
| US-20130098775-A1 | Glucose biosensor with improved shelf life | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013059534-A1 | GLUCOSE BIOSENSOR WITH IMPROVED SHELF LIFE | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | WO | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-8226965-B2 | Methods of treating fungal, yeast and mold infections | NANOBIO CORPORATION (US) | 2012-07-24 | — | — | US | claimed |
| US-20120064136-A1 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS | NANOBIO CORPORATION | 2012-03-15 | — | — | US | claimed |
| US-20100226983-A1 | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | NANOBIO CORPORATION | 2010-09-09 | — | — | US | claimed |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | NANOBIO CORPORATION | 2010-04-15 | — | — | US | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| US-20090304799-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| EP-4058059-B1 | NANOEMULSION COMPOSITIONS FOR TREATING AEROALLERGEN ASSOCIATED ALLERGY AND INFLAMMATION | UNIV MICHIGAN REGENTS (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-114989383-B | Preparation method of environment-friendly polyurethane foaming agent | 常州禄泽新材料科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-5100469-A | Colorant, carrier and meso-erythritol or a trihydroxy compound | XEROX CORPORATION (US) | 1992-03-31 | — | — | US | disclosed |
| US-5080906-A | With tris(hydroxymethyl)aminomethane | ZAMBON GROUP, S.P.A. (IT) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | PTGS2 2733/4885LMNA 3448/4885MEN1 969/4885 |
| US-20100092526-A1 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | CFTR, CCL11, ELANE | PTGS2 1404/4885LMNA 4380/4885MEN1 4120/4885 |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | PTGS2 1204/4885LMNA 3805/4885MEN1 4237/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | PTGS2 1764/4885LMNA 3248/4885MEN1 624/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | PTGS2 1204/4885LMNA 3805/4885MEN1 4237/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | PTGS2 1764/4885LMNA 3248/4885MEN1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.